Alzheimer's disease clinical trials: Changing the paradigm

Current Psychiatry Reports

Volumn 13, Issue 6, 2011, Pages 437-442

  Cummings, Jeffrey L ^a  

^a CLEVELAND CLINIC LOU RUVO CENTER FOR BRAIN HEALTH   (United States)

Author keywords

ADAS cog; Alzheimer's disease; Amyloid betaprotein; Amyloid imaging; Apolipoprotein genotype; APP mutations; Biomarkers; Cerebrospinal fluid; Clinical trials; Drug development; Frontotemporal dementia; Isoprostanes; MRI; Neurodegenerative diseases; Presenilin mutations; Progranulin; Tau protein

Indexed keywords

AMIODARONE; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; BAPINEUZUMAB; BETA SECRETASE INHIBITOR; BIOLOGICAL MARKER; CHLOROQUINE; CHOLINESTERASE INHIBITOR; GAMMA SECRETASE INHIBITOR; GRANULIN; MEMANTINE; PROGRANULIN; TAU PROTEIN; UNCLASSIFIED DRUG; NEUROLEPTIC AGENT;

AGE DISTRIBUTION; ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN GENE; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; CONCEPTUAL FRAMEWORK; DISEASE COURSE; DISEASE SEVERITY; DRUG RESEARCH; DRUG RESPONSE; FRONTOTEMPORAL DEMENTIA; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; MINI MENTAL STATE EXAMINATION; MOLECULAR PATHOLOGY; NOTE; ONSET AGE; OUTCOME ASSESSMENT; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRESENILIN 1 GENE; PRESENILIN 2 GENE; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; SENSITIVITY AND SPECIFICITY; STUDY DESIGN; AGE; AGED; ARTICLE; DRUG DESIGN; FEMALE; GENETICS; MALE; MIDDLE AGED;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; APOLIPOPROTEIN E4; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 84855895591     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-011-0234-y     Document Type: Note

References (25)

1. Alzheimer's Association: 2010. Alzheimer's disease facts and figures. Alzheimers Dement. 2010;6(2):158-94.
2. Phrma. Medicines in development for Alzheimer's disease. Phrma Report (2010).
3. Cummings J. What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease? Biol Psychiatry. 2010;68(10):876-8.
4. Miller G. Is pharma running out of brainy ideas? Science. 2010;329(5991):502-4.
5. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009;73 (24):2061-70.
6. Blom ES, Giedraitis V, Zetterberg H, Fukumoto H, Blennow K, Hyman BT. Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype. Dement Geriatr Cogn Disord. 2009;27(5):458-64.
7. Sluimer JD, Vrenken H, Blankenstein MA, Fox NC, Scheltens P, Barkhof F, et al. Whole-brain atrophy rate in Alzheimer disease: Identifying fast progressors. Neurology. 2008;70(19 Pt 2):1836-41. (Pubitemid 351653952)
8. Mitchell SL, Teno JM, Kiely DK, Shaffer ML, Jones RN, Prigerson HG, et al. The clinical course of advanced dementia. N Engl J Med. 2009;361(16):1529- 38.
9. Tiraboschi P, Hansen LA, Masliah E, Alford M, Thal LJ, Corey- Bloom J. Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology. 2004;62 (11):1977-83. (Pubitemid 38738207)
10. Mortimer JA, Snowdon DA, Markesbery WR. The effect of APOE-epsilon4 on dementia is mediated by Alzheimer neuropathology. Alzheimer Dis Assoc Disord. 2009;23(2):152-7.
11. Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, Ringman JM, et al: Autosomal-dominant Alzheimer's disease: A review and proposal for the prevention of Alzheimer's disease. Alzheimers. Res. Ther. 3(1), 1 (2011). [Epub ahead of print].
12. Reiman EM, Langbaum JB, Tariot PN. Alzheimer's prevention initiative: A proposal to evaluate presymptomatic treatments as quickly as possible. Biomark Med. 2010;4(1):3-14.
13. Montine TJ, Quinn J, Kaye J, Morrow JD. F(2)-isoprostanes as biomarkers of late-onset Alzheimer's disease. J Mol Neurosci. 2007;33(1):114-9. (Pubitemid 47574948)
14. Alvarez A, Cacabelos R, Sanpedro C, Garcia-Fantini M, Aleixandre M. Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease. Neurobiol Aging. 2007;28(4):533-6. (Pubitemid 46282207)
15. Ewers M, Mielke MM, Hampel H. Blood-based biomarkers of microvascular pathology in Alzheimer's disease. Exp Gerontol. 2010;45(1):75-9.
16. Lee JM, Blennow K, Andreasen N, Laterza O, Modur V, Olander J, et al. The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. Clin Chem. 2008;54(10):1617-23.
17. Lovell MA, Lynn BC, Xiong S, Quinn JF, Kaye J, Markesbery WR. An aberrant protein complex in CSF as a biomarker of Alzheimer disease. Neurology. 2008;70(23):2212-8.
18. Yin GN, Lee HW, Cho JY, Suk K. Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases. Brain Res. 2009;1265:158-70.
19. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009;65(4):403-13.
20. Schofield EC, Halliday GM, Kwok J, Loy C, Double KL, Hodges JR. Low serum progranulin predicts the presence of mutations: A prospective study. J Alzheimers Dis. 2010;22(3):981-4.
21. Finch N, Baker M, Crook R, Swanson K, Kuntz K, Surtees R, et al. Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain. 2009;132(Pt 3):583-91.
22. Gijselinck I, Van Broeckhoven C, Cruts M. Granulin mutations associated with frontotemporal lobar degeneration and related disorders: An update. Hum Mutat. 2008;29(12):1373-86. (Pubitemid 352774891)
23. Mukherjee O, Wang J, Gitcho M, Chakraverty S, Taylor-Reinwald L, Shears S, et al. Molecular characterization of novel progranulin (GRN) mutations in frontotemporal dementia. Hum Mutat. 2008;29(4):512-21. (Pubitemid 351536990)
24. Capell A, Liebscher S, Fellerer K, Brouwers N, Willem M, Lammich S, et al. Rescue of progranulin deficiency associated with frontotemporal lobar degeneration by alkalizing reagents and inhibition of vacuolar ATPase. J Neurosci. 2011;31(5):1885-94.
25. Rosen HJ, Narvaez JM, Hallam B, Kramer JH, Wyss-Coray C, Gearhart R, et al. Neuropsychological and functional measures of severity in Alzheimer disease, frontotemporal dementia, and semantic dementia. Alzheimer Dis Assoc Disord. 2004;18 (4):202-7. (Pubitemid 40076149)